Analysts Set Alphatec Holdings, Inc. (NASDAQ:ATEC) PT at $17.56

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $17.56.

Several analysts recently commented on ATEC shares. Needham & Company LLC raised their price objective on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Tuesday, January 14th. Finally, Barclays raised their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd.

Insider Transactions at Alphatec

In related news, COO Scott Lish sold 27,453 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the sale, the chief operating officer now directly owns 867,677 shares in the company, valued at approximately $9,969,608.73. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the sale, the executive vice president now owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 222,376 shares of company stock worth $2,557,148 over the last ninety days. 22.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alphatec

A number of institutional investors have recently bought and sold shares of ATEC. SG Americas Securities LLC grew its holdings in Alphatec by 207.7% in the third quarter. SG Americas Securities LLC now owns 44,603 shares of the medical technology company’s stock valued at $248,000 after purchasing an additional 30,108 shares during the period. Creative Planning grew its holdings in Alphatec by 83.9% in the third quarter. Creative Planning now owns 48,611 shares of the medical technology company’s stock valued at $270,000 after purchasing an additional 22,171 shares during the period. Net Worth Advisory Group purchased a new stake in Alphatec in the third quarter valued at approximately $76,000. Tempus Wealth Planning LLC purchased a new stake in Alphatec in the third quarter valued at approximately $107,000. Finally, Courier Capital LLC grew its holdings in Alphatec by 105.3% in the third quarter. Courier Capital LLC now owns 39,000 shares of the medical technology company’s stock valued at $217,000 after purchasing an additional 20,000 shares during the period. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Stock Down 0.5 %

Shares of Alphatec stock opened at $10.61 on Monday. Alphatec has a one year low of $4.88 and a one year high of $15.69. The company has a market cap of $1.50 billion, a P/E ratio of -8.29 and a beta of 1.43. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The firm has a fifty day moving average of $10.48 and a two-hundred day moving average of $8.26.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.